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Objectives: The objective of the present study was to utilize dual asymmetric centrifugation (DAC) as a 
novel processing approach for the production of liposomes-in-hydrogel formulations. 
Materials and Methods: Lipid films of phosphatidylcholine, with and without chloramphenicol (CAM), were 
hydrated and homogenized by DAC to produce liposomes in the form of vesicular phospholipid gels with 
a diameter in the size range of 200-300 nm suitable for drug delivery to the skin. Different homogenization 
processing parameters were investigated along with the effect of adding propylene glycol (PG) to the 
formulations prior to homogenization. The produced liposomes were incorporated into a hydrogel made 
of 2.5 % (v/v) soluble β-1,3/1,6-glucan (SBG) and mixed by DAC to achieve a homogenous liposomes-in-
hydrogel-formulation suitable for topical application. 
Results and Discussion: CAM-containing liposomes with a vesicle diameter of 282 ± 30 nm and 
polydispersity index (PI) of 0.13 ± 0.02 were successfully produced by DAC after 50 minutes centrifugation 
at 3500 rpm, and homogenously (< 4 % content variation) incorporated into the SBG hydrogel. Addition of 
PG decreased the necessary centrifugation time to 2 minutes and 55 seconds, producing liposomes of 230 
± 51 nm and PI of 0.25 ± 0.04. All formulations had an entrapment efficiency of approximately 50%. 
Conclusions: We managed to develop a relatively fast and reproducible new method for the production of 
























Skin disorders are the fourth leading cause of nonfatal diseases at the global level (Hay et al., 2014). The 
potential of nanopharmaceuticals in treating local skin diseases, such as skin infections and wounds, has 
yet to be fully realized, however the extensive research efforts are expected to result in improved therapy 
outcome (DeLouise, 2012, Hurler and Škalko-Basnet, 2012). Nanosized delivery systems offer an 
opportunity for extensive innovation in nanomedicine, making them an attractive target in drug product 
development (Vanić et al., 2015). Nanosized drug delivery systems designed for improved skin therapy are 
expected to exhibit all, or at least some of the desired features, namely to be able to protect drug from 
degradation as well as improve penetration of drug into/through the skin (Couvreur and Vauthier, 2006). 
Among various nanosystems developed to improve skin therapy, our focus is on liposomes. Liposomal 
encapsulation of drugs for enhancement of drug deposition into the skin was first introduced by Mezei 
and his colleagues in the early 1980s (Mezei and Gulasekharam, 1980). Already in 1988, the first topical 
liposomal preparation, Pevaryl Lipogel®, produced by Cilag A.G. became available on the market. The fact 
that most topical liposomal preparations brought to the industrialization phase carry drugs that are 
targeted to the dermal region of the skin, shows that liposomal carriers are well-suited for this kind of 
application (Vanić et al., 2015).  
However, liposomes are aqueous dispersions and their fluid nature could be a limitation for skin 
administration in respect to residence time and leakage from the skin surface. For these reasons, 
liposomes should be incorporated into suitable vehicles (bases) of appropriate rheological features. The 
ideal vehicle exhibits appropriate rheological and textural properties, is compatible with both nanosystem 
and incorporated drug, stable during the storage, and safe to use (Hurler et al., 2013).  
Although liposomes have been widely studied as superior drug carriers destined for topical administration 
onto the skin, the manufacturing methods applied in their production remain to be difficult to scale up 
and limited in many aspects of drug development (Mozafari, 2005).  
To overcome the limitations of liposomal manufacturing based on the classical methods, we have in the 
present study investigated dual asymmetric centrifugation (DAC) as a novel manufacturing method for 
preparing liposomes-in-hydrogel for topical application. DAC was first introduced by Massing and his group 
as a new method for producing liposomes for parenteral application (Massing et al., 2008), and the method 
was further exploited by others (Hirsch et al., 2009, Tian et al., 2010, Adrian et al., 2011, Helm and Fricker, 
2015).  The DAC-technology offers rapid mixing of viscous material, based on the rotation of the sample 
around two axes, the central axis and a second axis in the center of the sample container. The 
homogenizing effect is obtained when the material is semisolid and sticks to the wall of the container, 
bringing the combination of the two contra-rotating movements into effect. Since topical products usually 
are viscous and semisolid and should adhere to the skin and retain there for a sufficient amount of time 
to allow the product to have the intended medical effect (Elnaggar et al., 2014), the desirable viscous 
consistence of the DAC-samples is ideal for topical products. Typically, liposomes for topical application 
are dispersed in polymeric materials such as hydrogels to form “classical liposomal hydrogel” (Elnaggar et 
al., 2014). These liposomes-in-hydrogel formulations must not be mistaken for vesicular phospholipid gels 
(VPGs), semisolid gels formed from concentrated liposomal dispersions. Here, numerous densely packed 
phospholipid vesicles (liposomes) form a gel-like structure, due to steric interactions between neighboring 
vesicles. VPGs were traditionally produced by high-pressure homogenization (Brandl, 2010). However, 
DAC seems more promising when aiming for production of bigger liposomes, and also to us, the closed 
system and possibility to process smaller batches is attractive for early phase formulation optimization to 
keep the laboratory expenses down.  
Our initial goal was to prove the suitability of DAC in preparing small-scale samples, therefore a custom-
made sample holder fitting 30 ml injection vials was selected for the VPG production, whereas the 
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liposomes-in-hydrogel mixing process was carried out in a Max 40 cup (Synergy Devices, Buckinghamshire, 
UK) with a capacity of 40 ml. Propylene glycol (PG) has a viscous nature, and is widely used as excipient in 
topical formulations, suitable to serve as a solvent for phospholipids and poorly water soluble drugs, and 
able to increase the deformability of liposome vesicles (Elmoslemany et al., 2012). Those were the reasons 
for preparing both PG-liposomes and conventional liposomes in this study. Finally, the suitability of using 
DAC-based mixing of liposomes into final “liposomes-in-hydrogel preparations” was tested. Thus, DAC was 
applied in two critical steps in the production process, namely both for the size reduction of the vesicles 
and for mixing and incorporation of vesicles into a hydrogel. The hydrogel chosen for this study was 2.5 % 
(v/v) soluble β-1,3/1,6-glucan (2.5 % SBG) in aqueous solution. SBG is known to activate macrophages and 
promote wound healing, and it has already shown promising results in the treatment of diabetic ulcers in 
the lower extremities (Zykova et al., 2014). Chloramphenicol (CAM) was chosen as a model antimicrobial 
drug, as it is a well-known antimicrobial, so far used most extensively in the topical treatment of ear and 
eye infections, but with potential in treatment of skin infections (Heal et al., 2009).  
 
Materials and methods 
Materials 
Lipoid S 100 (soybean lecithin, > 94 % phosphatidylcholine) was provided as a gift from Lipoid GmbH 
(Ludwigshafen, Germany). Water-soluble β-1,3/1,6-glucan gel (2.5 % SBG) was provided by Biotec 
BetaGlucans AS (Tromsø, Norway). Chloramphenicol, Fiske-Subbarow reducer, monobasic potassium 
phosphate, sodium chloride, 99.8 % anhydrous acetic acid, ≥ 37 % hydrochloric acid (HCl), chloroform 
(CHCl3) and methanol CHROMASOLV® (MeOH) were purchased from Sigma-Aldrich Chemie (Steinheim, 
Germany). Ammonium molybdate, disodium hydrogen phosphate dihydrate and 30 % hydrogen peroxide 
(H2O2) were purchased from Merck (Darmstadt, Germany). Concentrated sulphuric acid (H2SO4) was the 
product of May and Baker LTD (Dagenham, England). Polyamide membranes (pore size = 0.2 mm) used in 
drug release studies and cellulose acetate filters (0.2 µm) for filtration of buffer solution and mobile phase 
were purchased from Sartorius (Göttingen, Germany). Propylene glycol (PG), rubber stoppers and capsules 
for the injection vials were purchased from NMD - Norwegian Medical Depot AS (Oslo, Norway). 
 
Preparation of liposomes and liposomes-in-hydrogel formulations  
Formation of homogeneous lipid and lipid-drug films 
Lipid films were prepared in brown injection vials (Ø 36 mm, height 62.8 mm, capacity 30 ml) by dissolving 
200 mg Lipoid S 100 (PC) in 10 mL of chloroform:methanol (2:1, v/v). The organic solvents were evaporated 
at 24 °C under a stream of N2 for 1.5 hour in order to create a dry lipid film. A custom-made mixing device 
was used to provide constant rotation of the vial during evaporation to achieve an evenly distributed film 
on the bottom of the vial. The mixing device (Figure 1) was built using an Arduino Uno R3 microcontroller 
(Hobbykomponenter AS, Egersund, Norway), an Arduino Motor Shield (version 2) and a NEMA-17 size - 
200 steps/rev (50 rpm), 12V 350 mA stepper motor (Adafruit Industries, New York, USA). Epoxy clay was 
finally used to mold a custom holder were the injection vial could fit during rotation. 
For the lipid-drug films that contained CAM, 20 mg of drug was dissolved with 200 mg of PC prior to 





Hydration of lipid films 
For hydration of the lipid films, 200 µl phosphate buffered saline (PBS) pH 7.4 (2.98 g/L disodium hydrogen 
phosphate dihydrate, 0.19 g/L monobasic potassium phosphate and 8 g/L sodium chloride) was added 
when making conventional liposomes (C-Lip), whereas propylene glycol-containing liposomes (PG-Lip) 
were prepared by adding 100 µl of PG together with the 200 µl of PBS pH 7.4. The hydration procedure 
was as follows: Injection vials containing the samples was mixed for 5 minutes on a MS2 Minishaker vortex 
mixer (IKA-Werke, Staufen im Breisgau, Germany), and  allowed to rest for a minimum of 1 hour at room 
temperature. Finally, glass beads (GB) (Ø 2 mm) were added to the formulations and samples were stored 
at 4 °C overnight prior to size reduction.  
 
Homogenization of liposomes by dual asymmetric centrifugation 
Hydrated lipid films were processed into viscous liposome dispersions, or VPGs, by DAC in a SpeedMixer 
DAC 150 FVZ (Hauschild GmbH & Co KG, Hamm, Germany). A custom-made sample holder insert fitted for 
injection vials, described earlier by Massing and colleagues (Massing et al., 2008) was used during liposome 
processing, making it possible to insert the hydrated lipid films, directly into the SpeedMixer, facilitating 
closed handling. For formulations that demanded more than 5 minutes of centrifugation, the machine was 
restarted immediately after each 5-minute run until the desired total centrifugation time was achieved. 
Produced VPGs were diluted with PBS pH 7.4 to liposome dispersions (total volume of 2 mL) before 
characterization and dispersion in SBG gels to form the final liposomes-in-hydrogel formulation 
 
Mixing of liposomes into hydrogel 
To produce the liposomes-in-hydrogel formulations, 1 g of liposome dispersion and 9 g 2.5 % SBG was 
transferred to a Max 40 cup (Synergy Devices, Buckinghamshire, UK). Mixing was carried out at 3500 rpm 
for 5 minutes in the same SpeedMixer that was used for homogenization of liposomes.  
 
Comparison of probe-sonication with dual asymmetric centrifugation 
In order to compare the entrapment efficiency of our DAC-produced liposomes with a more well-known 
method, liposomes of the same composition as for the ones produced by DAC were prepared by probe-
sonication. The lipid-drug films were prepared using a rotary evaporator system (Büchi Labortechnik 
AG, Flawil, Switzerland) with a vacuum pump (20 minutes at 150 mbar, followed by 1 hour 
at 50 mbar) and a water bath (45 ± 1 °C) to remove the organic solvents. Dried films were 
then hydrated into more dilute liposome dispersions (10 mg/ml PC) with PBS pH 7.4 and 2 mL samples 
were sonicated (40 % amplitude) for 2 x 2 minutes on ice bath using a GEX500 high intensity ultrasonic 
processor (Sonics & Materials Inc., Newtown,  USA) with a 19 mm probe. 
 
Liposome and liposomes-in-hydrogel characterization 
Photon correlation spectroscopy 
Mean vesicle diameter and polydispersity index (PI) of the different liposome formulations was 
determined by photon correlation spectroscopy (PCS) with a Submicron Particle Sizer Model 370 (Nicomp 
Particle Sizing Systems, Santa Barbara, USA) as described earlier (di Cagno et al., 2011, Jøraholmen et al., 
2014) with minor modifications. All sample tubes were sonicated in PBS pH 7.4 for 10 minutes prior to use, 
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to eliminate any dust particles. The sample tube to be used during measurement were then filled with 
freshly filtered PBS pH 7.4 using syringe filters with a pore size of 0.2 µm (Acrodisc, PALL Life Sciences, 
Michigan, USA). The liposomal aliquots were diluted with PBS pH 7.4 until its intensity were within the 
range of 250 – 350 kHz. The samples were allowed to equilibrate in the Particle Sizer for 5 minutes before 
the analysis was started. Every analysis was performed in three 10-minutes cycles at 24 °C. Vesicle mode, 
automatic choice of channel width and volume weighting were used for data representation. Nicomp 
distribution was used for all measurements that had a Chi2-value > 3 and did not fit the Gaussian 
distribution accordingly.  In order to acquire a mean value for the measurements that fit a Nicomp 
distribution the size of the peaks were weighted according to their percentage and a weighted mean value 
was calculated. 
 
Entrapment efficiency  
Entrapment efficiency of the liposome formulations containing CAM were performed after the removal of 
free drug from the formulations by dialysis. The amount of drug present as free drug and liposome-
associated drug was then quantified by high-performance liquid chromatography (HPLC) analysis. 
Liposome formulations were diluted to a lipid concentration of 20 mg/ml prior to dialysis using a 
membrane with a Mw cut-off of 12–14000 Da (Medicell International Ltd., London, UK). PBS (pH 7.4) was 
used as dialysis medium. Duration of dialysis was 4 hours and was carried out at room temperature (23 
°C) and under sink conditions.  
Samples from both the dialysate and the liposome fraction were diluted with mobile phase prior to 
analysis. The mobile phase that was used, was a mixture of filtered water, MeOH and anhydrous acetic 
acid (55:44:0.1, v/v). Instrumentation setup consisted of a Waters e2795 Separations Module with a 
Symmetry C18 column guard and a XSELECT CSH C18 (2.5 µm 3.0x75 mm) column XP connected to a 
Waters 2489 UV/Visible detector (Waters, Dublin, Ireland). The flow rate was set to 0.4 mL/min, and both 
column and sample temperature were set to 30 ± 2 °C during separation.  
 
Lipid loss during processing 
Lipid content was determined using a modification of the Bartlett assay (Bartlett, 1959). To determine lipid 
loss on the glass beads used during processing of liposomes, the glass beads were immersed and rinsed in 
1 mL 0.5 M HCl. After rinsing, the beads were removed and the solution diluted up to a total volume of 10 
mL in a volumetric flask. 
For determination of total amount of lipid used by liposomes in the formulations, 50 µL samples of 
liposome dispersion were withdrawn after dialysis. All samples were diluted up to a total volume of 10 mL 
prior to the lipid quantification in the same manner as samples for lipid loss. 
A volume of 1 mL was withdrawn from all the diluted samples and mixed with 0.5 mL 10 N H2SO4, before 
heating them for 3 hours at 155 °C, and subsequent cooling to room temperature. When room 
temperature was reached, 2 drops of 30 % (v/v) H2O2 was added, and the mixtures was heated for an 
additional 1.5 hour at 155 °C. After all samples had reached room temperature again, they were mixed 
with 4.6 mL 0.22 % (v/v) ammonium molybdate and 0.2 mL Fiske-Subbarow reducer reagent, before the 
mixtures were heated for a final 7 minutes at 100 °C. The samples were analyzed calorimetrically at λ = 





Homogeneity of CAM in the formulations 
Homogeneity of active ingredient, CAM, in the liposomes-in-hydrogel formulations was determined by 
sampling (ca. 200 mg) from five different places within the hydrogel formulations. The withdrawn samples 
were diluted up to a total volume of 10 mL with HPLC mobile phase, filtered through a 0.2 µm filter 
(Acrodisc, PALL Life Sciences, Michigan, USA) and then analyzed by HPLC as described earlier. 
 
Drug release studies 
In vitro drug release studies were performed in order to compare the drug release from both our 
liposomes-in-hydrogel formulations compared to free drug in PG, free drug in SBG and liposomally 
entrapped drug in PBS (pH 7.4). The Franz cells (PermeGear, Bethlehem, USA) that were used had a volume 
of 12.0 or 12.1 mL and a surface area of 1.77 cm2. Polyamide membranes (Sartorius, Göttingen, Germany) 
were used as the model barrier, HPLC mobile phase were used as the acceptor medium and the 
temperature was set to 32 °C. A volume of 300 µL of each formulation were applied in the donor chambers. 
Samples (250 µL) were then withdrawn from the acceptor chamber at the following time points: 1, 2, 3, 4, 
5, 6, 7 and 8 hours after application of the formulations in the donor chambers. The drug concentration in 
all samples were determined by HPLC as described earlier. 
Stability testing 
Measurements of mean vesicle size, PI and quantification of total CAM content were repeated after 8 
weeks for liposome dispersions stored at 4 °C to check the stability of the formulation upon storage. 
Liposomes-in-hydrogel formulations stored at room temperature for 8 weeks were only retested for 
homogeneity of active ingredient. 
 
Statistical analysis 
Student’s t-test was used to identify differences between formulations and sample sets. A significance 
level where p < 0.05 was used when data was analyzed. 
 
Results and discussion 
The entrapping ability, biodegradability and non-toxic nature of liposomes make them attractive as drug 
delivery carriers. Moreover, they are also able to increase the amount of drug deposited into the upper 
layers of the skin and have been demonstrated to lower systemic drug levels, as compared with 
conventional formulations containing the same drug (Elsayed et al., 2007). This makes them highly 
promising for improved drug delivery to the skin (Ferreira et al., 2004, Chen et al., 2013).  
However, their successful application as drug delivery systems, relies not only on the proof of superiority 
as compared to more conventional formulations, but is also strongly dependent on the technical and 
economic feasibility of the liposomal formulation and its manufacturing process. Production procedures 
that easily can be brought from lab scale to an industrial scale, would speed up the development process, 
and finally bring new products to the market faster and within feasible economical frames. 
To formulate liposomal preparations acceptable as pharmaceuticals, some criteria are frequently 
mentioned to be important (Wagner et al., 2002, Huang et al., 2014):  (1) A unimodal narrow-size 
distribution, (2) a satisfactory chemical and physical stability, (3) a reproducible production process, (4) a 
high and constant entrapment efficiency, (5) a retained, depot-type drug-release from the vehicle is often 
anticipated, and (6) a production procedure that facilitates sterile and pyrogen-free products. The 
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relatively small number of liposomal products approved for human use so far, relative to the enormous 
research and development works on liposomes, might be explained by failure to meet any of these criteria, 
but high cost of the production process, especially on a larger scale, might as well keep products from 
entering the market (Mozafari, 2005). 
In the present work, we studied the potential use of DAC as a method for producing liposomes-in-hydrogel 
formulations suitable for topical wound treatment.   
 
Optimization of the methodology  
In an effort to keep the production process as simple as possible, we wanted to develop a method that 
utilized the full potential of the SpeedMixer and facilitated its use throughout the whole production of our 
liposomes-in-hydrogel formulations.  
When we began establishing the DAC-procedure we aimed to investigate the possibility of integrating the 
polyol dilution method as the first step of liposome production, inspired by the work of Kikuchi and 
colleagues (Kikuchi et al., 1994) and others (Pavelić et al., 1999, Pavelić et al., 2005), but in combination 
with DAC. The polyol dilution method makes it possible to avoid the use of harmful organic solvents in the 
production process, replacing them with PG to dissolve both CAM and PC. By dissolving the two 
compounds in PG at 60 °C prior to hydration and processing in the SpeedMixer, we were able to 
successfully produce liposomes. However, due to a disappointing entrapment efficiency of only 5 % CAM 
at best, we decided to try the conventional film hydration method. Since we wanted to avoid loss of 
material, unnecessary transfer and the need to produce our formulations in excess, we modified the film 
hydration method so, that the lipid film could be formed directly in an injection vial, and a custom-made 
setup for drying of lipid films was built (Figure 1). After evaporating solvents from the samples for 1.5 hour 
under a continuous stream of N2, the amount of residual solvent left in the vials was found to be < 0.8 % 
and judged as satisfactory for our purpose. 
It is generally accepted that for optimal dermal drug delivery into the skin, liposomes applied topically 
should be controlled for their physiochemical properties, such as vesicle size (Verma et al., 2003), drug 
entrapment efficiency, and lipid bilayer composition and elasticity/fluidity (Kirjavainen et al., 1999). Du 
Plessis et al. (du Plessis et al., 1994) suggested that the intermediate vesicle size of 300 nm gave the best 
deposition  of drug in the deeper skin layers, and the highest drug concentration in the reservoir. During 
our investigation and method optimization, we therefore aimed for a liposome size distribution between 
200-300 nm. Furthermore, we wanted to keep the amount of glass beads (GB) used during the processing 
as low as possible based on the findings by Massing and colleagues concerning the generation of glass 
particles from the beads (Massing et al., 2008).   
Table 1 shows the vesicle size and polydispersity index (PI) of empty conventional liposomes after 40 
minutes centrifugation time at 2400 and 3500 rpm with 25 % (w/w) GB, respectively. Mean diameter of 
liposomes produced at the two different speed levels were both within the desired size range of 200-300 
nm. The size difference is significant (p < 0.05) and points towards the importance of centrifugation speed 
on vesicle size, but there is no significant change in the PI. The lack of change in polydispersity of the 
samples when the speed is increased from 2400 to 3500 rpm might be due to the relatively small interval 
of 1100 rpm that was tested. When such a small interval is used it is difficult to observe anything other 





Entrapment of chloramphenicol 
When CAM was incorporated into the conventional liposomes, mean vesicle size increased from 214 ± 
12.5 nm to 426 ± 181.3 nm, whereas the PI changed from 0.20 ± 0.04 to 0.23 ± 0.10. Based on the increase 
of vesicle size, PI, and standard deviations, we decided to increase the content of GB from 25 to 50 % (w/w) 
and the centrifugation time from 40 to 50 minutes aiming to get a smaller and narrower size distribution 
of drug-containing vesicles. We found that although there was no significant change in vesicle size or PI 
when increasing the amounts of GB, the reproducibility improved (Figure 2). After 50 minutes 
centrifugation under the new settings, a mean vesicle diameter of 282 ± 30 nm with a PI equal to 0.13 ± 
0.02, was obtained. The significant (p < 0.05) increase in vesicle size for CAM-liposomes compared to 
empty liposomes, and the increase in amount of energy needed to produce liposomes within the desired 
size range (200-300 nm) indicate that CAM is mainly located in the lipid bilayer of liposomes. However, 
based on CAM’s solubility; 2.5 mg/ml in water (25 °C) and 150.8 mg/ml in propylene glycol, it is expected 
that CAM is in equilibrium with a dissolved portion of drug in the aqueous phase of the liposome 
dispersion. 
 
Effect of propylene glycol on liposomal characteristics 
We obtained an entrapment efficiency close to 50 % for both conventional liposomes and PG-liposomes 
(Table 2), and PG did not seem to affect the entrapment of CAM in the lipid bilayer. It was however critical 
to hydrate lipids and drug from a lipid film, as only 5% entrapment was obtained when liposomes were 
prepared with the conventional polyol method. Results from the comparison with the probe-sonication 
showed that even though bigger liposomes with a higher PI were obtained (836.1 nm and PI = 0.512), 
entrapment was only 30.13 ± 0.15 %, making DAC a superior method. DAC also seem to be superior to 
extrusion when it comes to entrapment of CAM as Engesland and colleagues achieved an entrapment 
efficiency of only 32.5 ± 2.8 % (drug:lipid ratio of 32.5 ± 2.8 µg/mg) after size reduction of liposomes (667 
nm) by nitrogen-driven extrusion while using exactly the same lipid and drug composition as applied in 
this study (Engesland et al., 2015). In the studies by Pavelić and colleagues (Pavelić et al., 2004), the starting 
CAM:lipid ratio was 2.5 times higher than in this present study; 4:4 (w/w)  relative to 1:10 (w/w), 
respectively. From this a final drug entrapment of 24.8 ± 3.1% (proliposome method) and 30.2 ± 4.1% 
(polyol method) was obtained. It seems that our results give the most successful method regarding 
entrapping the highest fraction of the added drug into the liposomes. This is very promising as it makes it 
feasible to skip the time consuming process of separating free drug from the liposomes before mixing 
them into the hydrogel/vehicle. To avoid the separation step is also critical when a relative high content 
of liposomes and drug in the hydrogel is aimed for, as both dialysis and size exclusion chromatography will 
demand the VPGs to be diluted for removal of the unentrapped drug. However, when looking at the drug 
entrapment values and calculating the drug to lipid ratio, Pavelić and co-workers obtained  a ratio of 76.1 
± 8.3 µg/mg (polyol dilution) and 62.7± 8.6 µg/mg (proliposomes)  (Pavelić et al., 1999). For liposomes 
composed of PC:PG (molar ratio 9:1) they obtained a similar values of 75.5 ± 10.3 µg/mg (polyol dilution) 
and 62.0 ± 7.8 µg/mg  (proliposome) (Pavelić et al., 2004). The entrapment was slightly higher than what 
we achieved with DAC; 52.2 ± 1.0 µg/mg (C-Lip-CAM) and 50.8 ± 4.2 µg/mg (PG-Lip-CAM) respectively, 
which indicate that it might still be possible to increase the drug:lipid ratio for our DAC-method. However, 
the preliminary results indicate that increasing the initial drug:lipid ratio, results in a higher content of free 
drug, which is not ideal if we want to avoid the separation of free drug from the formulation before 
incorporation into the hydrogel vehicle. 
After the addition of 24.8 % (w/w) PG to the formulation prior to the size reduction and homogenization, 
we observed a significant decrease in the time needed to obtain liposomes with a diameter of 200-300 
nm. Centrifugation time decreased from 50 minutes to 2 minutes and 55 seconds with 50 % (w/w) GB 
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(Table 2). Entrapment efficiency of CAM did not change compared to the formulations without PG; 
however the PI increased significantly (Table 2). The observed increase in PI is both a result of the reduced 
centrifugation time and addition of PG. Reduction of centrifugation time seems to give a decreased 
homogenization and more polydisperse samples (Figure 2 and Table 2). The presence of PG seems to lower 
the amount of energy needed to reduce the size of the liposomes; this observation is consistent with PG’s 
solubilizing effect on lipids and the PG molecules ability to intercalate with the lipid bilayer and thus allow 
a tighter packing of the lipids and smaller vesicle diameter (Castangia et al., 2013, Manca et al., 2014, Palac 
et al., 2014). 
 
Lipid loss and degradation during processing 
Neither CAM, amount of GB nor PG affected significantly the amount of lipids lost during processing (Figure 
3). The result, however, may indicate a trend towards less lipid loss with a decrease in the amount of GB 
and addition of PG. This is also reasonable, and might be explained by a decrease in the overall surface 
area available for the lipids to stick to when the number of GBs is reduced, and an increase in lipid solubility 
when PG is added. However, the lipid loss was judged acceptable for all settings used.   
The temperature of samples were recorded with an infrared thermometer, both before and after 
centrifugation, to determine the possibility for lipid degradation.   However, the observed elevation in 
sample temperature was only in the range of 7-10 °C from a starting temperature of 25 °C for both types 
of formulations. As Massing and colleagues previously showed (Massing et al., 2008), the degree of lipid 
degradation within the same temperature range is negligible. Our sample temperature did not exceed 50 
± 1 °C, and we therefore found the possibility of significant lipid degradation unlikely. 
 
Homogeneity of liposomes-in-hydrogel formulations 
In comparison to other methods used for the mixing of liposomal dispersion into hydrogels, such as using 
a standard electrical mixer (Škalko et al., 1998) or mixing it in by hand (Hurler et al., 2012), the SpeedMixer 
has the advantage of assuring fast, homogenous mixing of the formulations without the introduction of 
air bubbles/pockets. Actually, we observed that mixing with the SpeedMixer also removed air bubbles 
from viscous material during processing. Mixing of formulations using the SpeedMixer also allows 
production of more concentrated samples, for instance by mixing VPGs directly into the hydrogel vehicle. 
Hence, it makes it possible to increase the overall lipid and drug content, which is advantageous when 
aiming for the skin treatment of both chronic wounds and burn wounds with antimicrobials, where a 
higher drug concentration than what have been possible with liposomes-in-hydrogel formulations 
previously, may be required. The test for homogeneity of active ingredient in the final liposomes-in-
hydrogel formulations produced with the SpeedMixer showed high homogeneity of the samples with an 
average content of 8.36 ± 0.12 mg CAM per 10 g of gel formulation, and a variation < 4 % (Table 3). 
 
Drug release studies 
Preliminary results from the in vitro drug release studies comparing the release from hydrogel 
formulations for both conventional liposomes (Figure 4) and PG-liposomes (Figure 5) with liposomes 
dispersed in PBS (pH 7.4), free drug dissolved in PG and free drug in hydrogel, indicate that our liposomes-






The liposomes dispersed in SBG gel are difficult to analyze with regard to mean vesicle diameter and PI 
due to polymer network and presence of polymer aggregates. Thus, the liposome dispersions stored at 4 
°C were used as stability indicators, and change in size and PI were determined after 8 weeks storage and 
compared with the liposome size of the same samples right after preparation.  
Our results showed that the mean vesicle diameter changed for two of the three samples (Table 4). 
However, the change was minor (11 and 3 nm, respectively), and the PI immediately after preparation and 
after 8 weeks of storage shows that the values have decreased (p < 0.05) for all of the three samples, 
indicating that system is further stabilized after preparation and remained stable upon storage.  
 
Total CAM content in liposome dispersions containing PG stored at 4 °C decreased 5 ± 3 % after eight 
weeks of storage, while we observed a significant difference with an average decrease of 11 ± 1 % for the 
liposomes-in-hydrogel formulations stored at 23 °C (Figure 6). The difference in stability of the drug in 
these two preparations might be explained both by the difference in storage temperature and the 
dispersion media. In addition, the final concentration of the drug also differed. The choice of storage 
conditions for liposomes-in-hydrogel formulations was however done in accordance with the 
manufacturer recommendations, which was that storage at 4 °C was not possible for hydrogels made of 
SBG due to changes in the integrity of the polymer network at lower temperatures (personal 
communication). Thus, liposomes-in-hydrogel formulation made with SBG had to be stored at 23 °C to 
ensure optimal conditions for the polymer network. In both instances, the formulations were also 
protected from light. A study performed by Boer and Pijnenburg with CAM solutions (pH 7.2) under similar 
condition in the dark (4 °C and 21 °C) (Boer and Pijnenburg, 1983), showed the same kind of temperature-
dependent difference in degradation of CAM as observed for our samples. The stability limitations of CAM 
is well-known, and is explained by CAM hydrolysis into a glycol-derivative and CHCl2COOH in the presence 
of water (and light) (Lv et al., 2005). However, the rate of degradation observed by Boer and Pijnenburg 
was lower at both temperatures compared to our results, suggesting an increased rate of degradation in 
our liposome-in-hydrogel formulations. The positive effects of incorporating liposomes in other types of 
hydrogels, such as obtaining a sustained drug release effect, preventing leakage of entrapped drug and 
improved bioadhessiveness of the formulation to the skin, has already been proven (Škalko et al., 1998, 
Hurler et al., 2012). Thus, the main focus for further improvement of this specific formulation should be 
on the ways to minimize drug degradation and assure a satisfactory shelf-life. Overall, our findings might 
suggest that instant mixing of CAM-containing liposomes into hydrogel right before application might be 
the simplest way to solve the stability issue, but further studies and investigation on alternative strategies 
are still needed.  
 
Conclusions 
We successfully developed a new, straightforward and reproducible method for the production of 
liposomes-in-hydrogel formulations by the use of DAC. The method enabled the production of 
homogenous liposomes-in-hydrogel formulations with a higher lipid and drug content than what have 
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Figure 1: Illustration of the custom-made mixing device: (A) tube for N2 with a glass tip that directs the gas 
towards the vial; (B) injection vial with holder mounted on stepper motor; (C) Motor shield that drives the 





Figure 2: Effect of glass beads and chloramphenicol (CAM) on mean vesicle size (diameter) and 




Figure 3: Effect of glass beads on the lipid loss (n ≥ 3). 
 
 
Figure 4: Drug release from conventional liposomes-in-hydrogel formulation compared to the release of 
conventional liposomes in PBS (pH 7.4), free drug dissolved in PG and free drug in SBG (n = 3). 
 
 
Figure 5: Drug release from PG-liposomes-in-hydrogel formulation compared to the release of PG-




Figure 6: Changes in drug content in liposomes-in-hydrogel formulations upon storage (n = 3). 
 
Table 1. Effect of centrifugation speed on liposomal characteristics (n = 3). 
 
Table 2. Characteristics of liposomes (n ≥ 3). 




(nm ± SD) 
PI ± SD 
2400 264 ± 8.3 0.23 ± 0.026 





(nm ± SD) 
PI ± SD 
Entrapment 
efficiency 
(% ± SD) 
C-Lip-CAM 
(50 % GB) 
50 min 282 ± 30 0.13 ± 0.02 51.2 ± 2.3 
PG-Lip-CAM 
(25 % GB) 
2 min 55 sec 278 ± 66 0.31 ± 0.03 47.7 ± 3.6 
PG-Lip-CAM 
(50 % GB) 
2 min 55 sec 230 ± 51 0.25 ± 0.04 49.7 ± 2.8 
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Table 3. Drug homogeneity in the final liposomes-in-hydrogel formulations expressed as the average 















Significant difference (p < 0.05) observed upon storage. 
Formulation 
Drug content 
(mg/10 g gel ± RSD) 
1 8.37 ± 3.15 % 
2 8.21 ± 3.90 % 
3 8.50 ± 1.53 % 
Formulation 
Immediately after preparation 8 weeks (4 °C) 
Mean diameter  
(nm ± SD) 
PI ± SD 
Mean diameter 
(nm ± SD) 
PI ± SD 
1 201.2 ± 3.5  0.240 ± 0.01 201.2 ±  2.9 0.197 ± 0.02* 
2 288.8 ± 59.0 0.288 ± 0.03   242 ± 23.5* 0.239 ± 0.02* 
3 199.8 ± 0.9  0.206 ±  0.01 203.9 ± 2.3* 0.190 ± 0.01* 
